Patents by Inventor Jeong Hyun Ryou

Jeong Hyun Ryou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF
    Publication number: 20220332711
    Abstract: Novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food are disclosed. The novel N2-phenylpyrimidine-2,4-diamine compounds show potent inhibitory efficacies on EGFR mutations and thus, can be effectively used for the treatment of cancer with EGFR mutations.
    Type: Application
    Filed: March 31, 2022
    Publication date: October 20, 2022
    Applicant: BRIDGE BIOTHERAPEUTICS, INC.
    Inventors: Chulwon KIM, Koo LEE, GwangHee LEE, Taiguang JIN, Yong-Hee LEE, Jeong-Hyun RYOU, Jehrod BRENNEMAN, Sang Uk KANG
  • Polypeptide capable of binding to vascular endothelial growth factor, and use thereof
    Patent number: 10508138
    Abstract: The present disclosure relates to a novel polypeptide capable of binding specifically to vascular endothelial growth factor, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism including the expression vector, a method of producing the polypeptide using the recombinant microorganism, a composition for treating or preventing age-related macular degeneration or cancer, which comprises the polypeptide, and a method for preventing or treating age-related macular degeneration or cancer, which comprises administering the composition for treating or preventing age-related macular degeneration or cancer, which comprises the polypeptide. The disclosed polypeptide is capable of binding to vascular endothelial growth factor to inhibit the activity thereof, and thus can be widely used as an agent for treating and preventing various diseases associated with vascular endothelial growth factor (VEGF).
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: December 17, 2019
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Hak-Sung Kim, Da Eun Hwang, Jeong Hyun Ryou
  • NOVEL POLYPEPTIDE CAPABLE OF BINDING TO VASCULAR ENDOTHELIAL GROWTH FACTOR, AND USE THEREOF
    Publication number: 20180170980
    Abstract: The present disclosure relates to a novel polypeptide capable of binding specifically to vascular endothelial growth factor, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a recombinant microorganism including the expression vector, a method of producing the polypeptide using the recombinant microorganism, a composition for treating or preventing cancer, which comprises the polypeptide, and a method for preventing or treating cancer, which comprises administering the composition for treating or preventing cancer, which comprises the polypeptide. The disclosed polypeptide is capable of binding to vascular endothelial growth factor to inhibit the activity thereof, and thus can be widely used as an agent for treating and preventing various diseases associated with vascular endothelial growth factor (VEGF).
    Type: Application
    Filed: September 16, 2015
    Publication date: June 21, 2018
    Inventors: Hak-Sung Kim, Da Eun Hwang, Jeong Hyun Ryou